Multimodal neuroimaging provides a highly consistent picture of energy metabolism, validating 31P MRS for measuring brain ATP synthesis by Chaumeil, M. et al.
HAL Id: hal-02155689
https://hal.archives-ouvertes.fr/hal-02155689
Submitted on 17 Sep 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Multimodal neuroimaging provides a highly consistent
picture of energy metabolism, validating 31P MRS for
measuring brain ATP synthesis
M. Chaumeil, J. Valette, M. Guillermier, E. Brouillet, F. Boumezbeur, A.-S.
Herard, G. Bloch, P. Hantraye, V. Lebon
To cite this version:
M. Chaumeil, J. Valette, M. Guillermier, E. Brouillet, F. Boumezbeur, et al.. Multimodal neuroimag-
ing provides a highly consistent picture of energy metabolism, validating 31P MRS for measuring brain
ATP synthesis. Proceedings of the National Academy of Sciences of the United States of America , Na-
tional Academy of Sciences, 2009, 106 (10), pp.3988-3993. ￿10.1073/pnas.0806516106￿. ￿hal-02155689￿
Multimodal neuroimaging provides a highly
consistent picture of energy metabolism, validating
31P MRS for measuring brain ATP synthesis
Myriam M. Chaumeila, Julien Valettea, Martine Guillermierb, Emmanuel Brouilletb, Fawzi Boumezbeura,
Anne-Sophie Herarda,b, Gilles Blocha,c, Philippe Hantrayea,b, and Vincent Lebona,c,1
aCommissariat a` l’Energie Atomique (CEA)-I2BM-Medical Imaging Research Center (MIRCen), and bCentre National de la Recherche Scientifique-Unite´ de
Recherche Associe´e 2210-MIRCen, 92265 Fontenay-aux-Roses, France; and cCEA-I2BM-NeuroSpin, 91191 Gif-sur-Yvette, France
Edited by Robert G. Shulman, Yale University, New Haven, CT, and approved December 22, 2008 (received for review July 10, 2008)
Neuroimaging methods have considerably developed over the last
decades and offer various noninvasive approaches for measuring
cerebral metabolic fluxes connected to energy metabolism, includ-
ing PET andmagnetic resonance spectroscopy (MRS). Among these
methods, 31P MRS has the particularity and advantage to directly
measure cerebral ATP synthesis without injection of labeled pre-
cursor. However, this approach is methodologically challenging,
and further validation studies are required to establish 31P MRS as
a robust method to measure brain energy synthesis. In the present
study, we performed a multimodal imaging study based on the
combination of 3 neuroimaging techniques, which allowed us to
obtain an integrated picture of brain energy metabolism and, at
the same time, to validate the saturation transfer 31P MRS method
as a quantitativemeasurement of brain ATP synthesis. A total of 29
imaging sessionswere conducted tomeasure glucose consumption
(CMRglc), TCA cycle flux (VTCA), and the rate of ATP synthesis (VATP)
in primate monkeys by using 18F-FDG PET scan, indirect 13C MRS,
and saturation transfer 31P MRS, respectively. These 3 complemen-
tary measurements were performed within the exact same area of
the brain under identical physiological conditions, leading to:
CMRglc  0.27  0.07 molg1min1, VTCA  0.63  0.12
molg1min1, and VATP  7.8  2.3 molg1min1. The con-
sistency of these 3 fluxes with literature and, more interestingly,
one with each other, demonstrates the robustness of saturation
transfer 31P MRS for directly evaluating ATP synthesis in the living
brain.
glycolysis  TCA cycle  oxidative phosphorylation  NMR spectroscopy 
metabolic fluxes
Numerous brain disorders, like neurodegenerative diseases,are associated with impairment in energy metabolism. This
observation has been driving considerable technological devel-
opments in medical imaging, aiming at measuring brain energy
metabolism. PET combined with 18F-2-f luoro-2-deoxy-D-
glucose (18F-FDG) injection has been used in research on
normal and pathological brain for 30 years (1–3). More
recently, magnetic resonance spectroscopy (MRS) has brought
new tools for imaging cerebral energy fluxes (4–16).
However, methodological developments are still needed to
answer the clinical need for earlier diagnosis and follow-up of
neurodegenerative pathologies. Although PET detection of 18F-
FDG has proven efficient to map cerebral glucose consumption
(CMRglc), this technique does not directly reflect energy stor-
age and utilization that is mainly derived from glucose oxidation.
Also, PET is unlikely to become widely accessible, due to its
invasiveness and cost. However, magnetic resonance is of wide-
spread use for anatomical imaging, and clinical scanners can be
equipped for metabolic imaging at limited cost. Indeed, MRS
has proven powerful to measure brain energy metabolism by
detecting 13C, 17O, or 31P nuclei, which only require dedicated
radiofrequency components. Quantitative measurement of ce-
rebral oxidative metabolism by 13C (4–11) or 17O (14–16) MRS
has been demonstrated. However, these approaches require i.v.
injection of expensive precursors followed by time-consuming
acquisition. In contrast, 31P MRS has the potential to measure
the cerebral rate of ATP synthesis VATP without any injection,
using the magnetization transfer technique as originally dem-
onstrated by Brown et al. (17). Up to now, only 2 measurements
of cerebral VATP have been reported in rodents (12, 18), and 1
in humans (13). MRS-derived VATP reported in these pioneer
studies appeared consistent with literature values and coupled
with brain activity over a large range of anesthesia (18). How-
ever, MRS-derived VATP may be contaminated by a near-
equilibrium exchange reaction between inorganic phosphate (Pi)
and ATP catalyzed by the glycolytic enzymes GAPDH and
phosphoglycerate kinase (PGK). Such a contamination, leading
to an overestimation of the NMR-detected VATP, was inconsis-
tently reported on yeast suspensions (19), with a possible de-
pendence on the growth medium. MRS-derived VATP was also
shown to be contaminated by glycolytic enzymes ex vivo on
perfused peripheral organs (20, 21), on rodent skeletal muscle
(22), and human skeletal muscle (23). Given these elements,
further studies are required to establish 31P magnetization
transfer as a reliable quantitative method for measuring the
cerebral rate of energy synthesis VATP.
In this context, our purpose has been to validate the 31P MRS
measurement of brain VATP, by comparing the rate of ATP
synthesis measured in primates with CMRglc and TCA cycle rate
(VTCA) measured by PET and 13C MRS, respectively. Under
normal physiological conditions, glucose breakdown (through
glycolysis and TCA cycle) is stoechiometry coupled to ATP
synthesis, so that theoretical VATP can be calculated from the
measured CMRglc and VTCA, providing a direct way to validate
MRS-measured VATP.
Results show that CMRglc and VTCA measured in the primate
brain are highly consistent, showing the expected 1:2 stoechio-
metry between glycolysis and TCA cycle (1 glucose giving rise to
2 pyruvate molecules). Also, the theoretical value of VATP
derived from CMRglc and VTCA is very close to that directly
measured using 31P MRS and magnetization transfer. These
results demonstrate that 31P MRS is a reliable method to
measure brain ATP synthesis in vivo.
Results
High-resolution scout MRI of the monkey brain is presented on
Fig. 1, showing the 8-mL volume of interest (VOI) where the 3
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metabolic f luxes were measured. Anatomical landmarks on
coronal, axial, and sagital images made it possible to reposition
the VOI identically for all imaging sessions.
A typical 18F-FDG PET image (axial view; acquisition time, 20
min) is presented on Fig. 2A. The corresponding 18F time activity
curve in the selected VOI and the experimental 18F arterial time
activity curve are plotted in Fig. 2B. Kinetic analysis of 18F-FDG
uptake produced an estimation of 18F-FDG-6-P and 18F-FDG
contributions to total activity (Fig. 2B), leading to CMRglc 
0.27  0.07 molg1min1.
Fig. 3A shows a stacked plot of difference 1H-{13C} spectra
(averaged over the 8 13C NMR sessions) acquired during an i.v.
infusion of [U-13C6] glucose. Corresponding 13C-enrichment
time courses of glutamate C3 and C4 are presented in Fig. 3B.
The continuous lines represent the best fit to experimental data
according to the metabolic model. This analysis leads to VTCA 
0.63  0.12 molg1min1.
The Pi region of 31P spectra acquired with -ATP saturation
for 4 different saturation times (0.5, 1.0, 1.5, and 2 s) is presented
in Fig. 4A (averaged over the 15 31P NMR sessions). It shows that
Pi amplitude is decreased while the saturation time is increased.
Note that Pi decrease on this figure is due to both saturation
transfer effect and RF bleed over effect, the later explaining the
decrease of resonances surrounding Pi (mostly phosphodiesters
and phosphomonoesters3 and 7 ppm, respectively); 31P spectra
were corrected for RF bleed over by subtracting -ATP satu-
rated spectra from control spectra where saturation was applied
symmetrically to -ATP. Inversion-recovery experiments
yielded a mean value of T1mix  2.05 s. Consequently, the
averaged Pi attenuation vs. tsat was fitted fixing the following
parameters: T1mix  2.05 s,   60°, TR  2.95 s. The best fit is
shown on Fig. 4B. The estimation of kf and T1int from averaged
MS(tsat)/MC(tsat) fitting and Monte Carlo simulation yielded kf 
0.10 0.03 s1 and T1int 2.1 0.4 s. Cerebral Pi concentration
was fixed to [Pi]  1.3 mM, according to literature values
(24–29). By using a brain density of 1g/mL, we obtained the ATP
synthesis rate VATP  7.8  2.3 molg1min1.
The 3 metabolic f luxes measured in this study and their
metabolic couplings are presented on Fig. 5.
Discussion
Consistency of Each Measured Flux with Literature Values. Taken
independently, the CMRglc and VTCA fluxes measured in this
study are consistent with literature values of brain energy
metabolism for anesthetized animals (30–33), and particularly
with the values reported by Boumezbeur et al. (30) in the monkey
brain (CMRglc  0.23  0.03 molg1min1; VTCA  0.53 
0.13 molg1min1). The small differences between these
values and CMRglc and VTCA measured in this study could be
explained by differences in VOI position, and consequently by
different contributions of gray and white matter to the detected
fluxes: in our study, gray matter accounts for 58  2% of the
detected brain tissue, as measured on high resolution T1-
weighted images (data not shown). This percentage is likely to be
higher than gray matter content in the voxel detected by Bou-
mezbeur et al. (30), which was located deeper in the brain and
included significantly less cortical areas. Given the strong de-
Fig. 1. Three-dimensional MRI images acquired in 1 monkey. The position of
the VOI in which CMRglc, VTCA, and VATP were measured is presented on
coronal (A), axial (B), and sagital images (C).
Fig. 2. CMRglc measurement by 18F PET. (A) VOI from which the total 18F
activity was extracted, (B) corresponding 18F-FDG PET time-activity curve ()
and best fit by the 2-tissue compartment model (bold solid line). Arterial
function measured in the same session is presented (thin solid line). Modeled
contributions of 18F-FDG and 18F-FDG-6-P are shown (gray lines).
Fig. 3. VTCA measurement by indirect 13C NMR. (A) Stack plot of 1H-{13C}
difference spectra in glutamate C3 and C4 region. Glutamate 13C enrichment
appears at the frequency of C3 and C4 mother resonances on our 1H difference
spectra. Spectra were post processed by a 5 Hz lorentzian line broadening. (B)
13C enrichments time courses (averaged over 8 sessions) measured for gluta-
mate C3 (‚), glutamate C4 (), and best fit to the data (solid lines).
Fig. 4. VATP measurement by 31P saturation transfer NMR. (A) Pi region of 31P
spectra acquired on -ATP saturation for 4 different saturation times (0.5,
1.0, 1.5, and 2 s). Pi amplitude decreases as saturation time is increased. (B)
Pi attenuation [MS(tsat)/MC(tsat)] vs. saturation time tsat. The solid line is the
best fit to experimental Pi attenuation (). The dotted lines indicate the
lower and upper limits of the fit based on kf and T1int SD.
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pendence of glucose metabolism on gray matter content (7), a
slight difference in gray matter fraction might explain our higher
CMRglc and VTCA values (0.27 and 0.63 molg1min1, re-
spectively). PET measurements of CMRglc have been reported
recently in the monkey brain, and found to be close to 0.3
molg1min1 in brain areas similar to our VOI (31). This
value is very close to our measurement (0.27 molg1min1).
Our VTCA values (0.63  0.12 molg1min1) are in agree-
ment with reported human values that range from 0.57 to 0.77
molg1min1 (6, 8, 9, 11).
The measurement of VATP reported in this article is, to our
knowledge, the first one performed in the monkey brain. Com-
pared with the only one reported measurement of cerebral VATP
that was performed in humans (13), the VATP value reported in
this study appears slightly lower (7.8  2.3 molg1min1 vs.
12.1  2.8 molg1min1). However, the SD ranges of both
measurements overlap so that no significant difference can be
inferred.
Consistency Between CMRglc and VTCA. In this study, a [VTCA/
CMRglc] ratio of 2.25 is measured, reflecting the metabolic
coupling between glycolysis and TCA cycle. Considering that
glucose is the unique metabolic fuel under normal physiological
conditions, a [VTCA/CMRglc] ratio of 2 would be expected,
because glycolysis produces 2 molecules of pyruvate per glucose.
The measured [VTCA/CMRglc] ratio is 12.5% higher than the
expected theoretical value, leaving room for a possible contri-
bution of fatty acids to the TCA cycle (CMRFA  VTCA  2
CMRglc). However, given the fact that the SD on each flux
(VTCA and CMRglc) is 15%, the [VTCA/CMRglc] ratio is not
high enough to claim a significant contribution of the fatty acid
pathway. The 12.5% excess over theoretical ratio could be partly
ascribed to experimental inaccuracy.
Potential Effect of Glycemia on the Measured Fluxes. Blood glucose
was measured during the course of PET and 13C-NMR sessions.
Glycemia measured at the beginning of 13C-NMR sessions
(before 13C glucose injection) and during the course of PET
measurements were all in the 3–5 mmolL1 normoglycemic
range; 13C measurement of VTCA was performed under hyper-
glycemia (9–15 mmolL1 in our study), because a several fold
increase in glycemia is required to bring 13C enrichment of blood
glucose up to 50%. In this context, one may wonder whether
CMRglc and VTCA are affected by blood glucose content.
CMRglc dependence on glycemia has been studied by several
groups, who concluded that brain glucose uptake is not affected
by acute hyperglycemia. Evidence for this result was demon-
strated in rodents as well as in humans (34, 35). Unfortunately,
VTCA dependence on glycemia has not been studied as thor-
oughly as CMRglc, due to the lack of method (besides 13C NMR)
for noninvasive measurement of the TCA cycle flux. It must be
kept in mind that VTCA measured using 13C-labeled glucose
includes the contributions of all possible substrates of acetyl-
CoA oxidation. Therefore, NMR-measured VTCA is directly
coupled to CMRO2 (14), as shown ex vivo on brain slices (36).
Since several studies have reported that CMRO2 remains inde-
pendent from glycemia in mammals (37, 38), the absence of
glycemic dependence can be reasonably extended to VTCA. Note
that glycemia was not measured during 31P-NMR sessions,
because VATP measurement does not require vascular catheteri-
sation. Due to the similarity of experimental conditions with
PET and preinfusion 13C-NMR sessions, it can be reasonably
considered that VATP was measured under normoglycemia.
Given these elements, one can assume that the metabolic f luxes
measured in our study were not noticeably affected by glycemic
differences.
Validation of VATP asMeasured by NMR.Given the values of CMRglc
and VTCA, the corresponding ATP synthesis rate VATP can be
theoretically expressed by establishing stoechiometry between
molecules of ATP and reducing equivalents (i) generated by the
TCA cycle and oxidative phosphorylation, (ii) generated by
glycolysis, and (iii) consumed by the fatty acid pathway. It is well
known that the degradation of 1 acetyl-CoA in the TCA cycle
leads to the production of 1 ATP, 3 NADH,H, and 1 FADH2,
and that glycolysis leads to the production of 2 pyruvate, 2 ATP,
and 2 NADH,H, a posteriori transformed in 2 FADH2 by
crossing the mitochondrial membrane. Also, the conversion of
pyruvate into acetyl-CoA in the mitochondrial matrix leads to
the production of 2 NADH,H. Under the hypothesis of all
pyruvates produced through glycolysis being converted into
acetyl-CoA, the rate of this reaction can be assumed to be equal
to CMRglc. Then, the corresponding VATP can be expressed as:
VATP
TH (2(PO)FADH22(PO)NADH,H2)CMRglc
 3PONADH,H(POFADH21)VTCACMRFA [1]
where (P/O)NADH,H and (P/O)FADH2 are the number of ATP
molecules per atom of oxygen produced by the degradation of 1
NADH,H and 1 FADH2, respectively, in the respiratory chan-
nel. Based on established values for the P/O ratios [(P/
O)NADH,H  2.3 and (P/O)FADH2  1.4; see ref. 39], the
theoretical rate of ATP synthesis expected from the rate of
CMRglc and VTCA we measured in the present study was:
VATPTH  8.3  1.8 molg1min1. This value is very close to
the NMR-measured VATP (7.8  2.3 molg1min1). The
slightly lower measured value could be explained by a partial
uncoupling between the generation of the proton gradient and
the use of this gradient for synthesis of ATP from ADP and Pi.
Possible explanation for partial uncoupling might involve spe-
cific uncoupling proteins like the brain-specific UCP4 (40, 41).
However, the theoretical expected value VATPTH is well within
the measurement error of our 31P-NMR measured VATP. There-
fore, our study does not allow us to conclude on significant
uncoupling process in the mammal brain.
To our knowledge, only one previous study was performed in
humans to assess the coupling between VTCA and VATP, mea-
sured by 13C NMR and 31P NMR, respectively (23). This study,
performed in skeletal muscle, reported the following values:
Fig. 5. Brain energy metabolism as measured by multimodal imaging:
18F-FDG was used to quantify CMRglc, 13C MRS was used to measure VTCA, and
31P MRS was used to measure VATP. The 3 fluxes are highly consistent, validat-
ing 31P MRS as a robust tool for quantifying brain ATP synthesis.
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VTCA  0.06 molg1min1 and VATP  5 molg1min1.
According to Eq. 1, the theoretical value of VATP expected from
the measured VTCA ranges from VATPTH  0.5 molg1min1
(assuming that FA is the sole substrate for muscle, i.e., CMR-
glc 0 and CMRFA 1⁄2VTCA) to VATPTH 0.8molg1min1
(assuming that glucose is the sole substrate, i.e., CMRglc 
1⁄2VTCA and CMRFA  0). Thus, the range of expected VATPTH
values is 10 to 6 times as low as 31P-NMR measured VATP (5
molg1min1), which demonstrates that the GADPH shunt-
ing is dominant in human skeletal muscle. In contrast, the
present study gives a cerebral VATP slightly lower than the
theoretical value expected from CMRglc and VTCA; thus, ruling
out the possibility of a contribution of reversible synthesis by
GADPH/PGK at the glycolytic level in the brain. Our data would
be consistent with the fact that Pi is mostly present in neurons
while a strong glycolytic component takes place in astrocytes as
postulated by Lei et al. (13). This explanation relies on the
hypothesis that lactate (provided by astrocytes through an
astrocyte-neuron lactate shuttle) is the major substrate for
neuronal oxidative metabolism. Although experimental evi-
dences argue in favor of lactate shuttle having a key role in
glutamatergic activation (42, 43), the significance of this shuttle
remains controversial (44, 45). More importantly, the extent of
physiological conditions under which the lactate shuttle domi-
nates direct neuronal glucose uptake remains to be explored. It
must be kept in mind that the animal and human metabolic
f luxes discussed here were measured under light anesthesia or
alpha state (peaceful awakefulness). Further studies will be
required to establish that lactate shuttle remains predominant
under those physiological conditions.
In conclusion, this study is, to our knowledge, the first report
of cerebral CMRglc, VTCA, and VATP measurements in the same
animals under identical physiological conditions. This unique
multimodal approach allows a cross-validation of the described
18F-FDG, 13C MRS, and 31P MRS techniques. In particular, this
is a direct in vivo validation of the 31P saturation transfer method
as a reliable measurement of the cerebral ATP synthesis rate.
Implementation of the 3 methodological approaches brings a
unique integrated picture of brain energy metabolism, from
glucose phosphorylation to mitochondrial ATP synthesis. This
multimodal approach will help to better understand mitochon-
drial energy defects that are thought to have a key role in
neurodegenerative illnesses (46, 47).
Materials and Methods
The study was conducted on 3 healthy male monkeys (macaca fascicularis,
body weight 5 kg) after they were fasted overnight. All experimental
procedures were performed in strict accordance with the recommendations of
the European Community (86/609) and the French National Committee (87/
848) for care and use of laboratory animals. For both PET and NMR sessions,
animals were identically anesthetized by a single ketamine-xylazine intramus-
cular injection followed by an i.v. infusion of propofol (200 g/kg/min),
intubated, and ventilated. The head was placed in the Sphinx position by using
a home made stereotaxic frame with bite-bar and ear rods. During NMR and
PET sessions, physiological parameters were monitored and remained stable
within normal ranges: 35–37 °C for body temperature, 50–60 mm Hg for
noninvasive blood pressure as measured with an air-cuff placed around the
arm, 90–110 min for cardiac frequency, 18–23 min for respiratory frequency,
and 35–40 mm Hg for expired CO2 saturation.
Experimental Design. Neuroimaging sessions. In this study, the experimental
plan aimed at measuring the 3 following metabolic fluxes in a same 2 	 2 	
2 cm3 cerebral VOI on the group of monkeys: (i) CMRglc using PET acquisitions
after i.v. injection of 18F-FDG (1-h acquisition time, 6 sessions: 2 per monkey);
(ii) VTCA using indirect 13C-NMR spectroscopy during an i.v. infusion of [U-13C6]
glucose (2-h acquisition time, 8 sessions: 2 to 3 per monkey); and (iii) VATP using
31P-NMR spectroscopic acquisition by saturation transfer (1.40-h acquisition
time, 15 sessions: 4 to 6 per monkey). Given the long acquisition time of NMR
measurements, animal welfare motivated our decision not to perform 13C-
NMR and 31P-NMR during the same session, and to allow at least 2 weeks
recovery between 2 subsequent imaging sessions for each monkey.
Each imaging modality has its own sensitivity to the measured metabolic
flux: under our experimental conditions, VTCA determination by 13C NMR was
less accurate than CMRglc determination by PET, likely due to the intrinsic low
sensitivity of NMR spectroscopy. VATP determination by 31P NMR was even less
accurate the VTCA determination, mostly due to the high number of measured
parameters required to assess VATP. Our purpose being to compare the 3
fluxes, the number of imaging sessions was empirically set to compensate for
sensitivity differences between modalities. This empirical design allowed
assessing the 3 fluxes with similar accuracies.
VOI positioning and multimodal registration. Proper comparison of the 3 meta-
bolic fluxes requires reproducible positioning of the VOI in the brain for all
imaging sessions. For 13C and 31P NMR sessions, high-resolution 3D MRI images
of the brain (gradient echo sequence, matrix 128	 128	 128, resolution 1	
1 	 1 mm3) were acquired to position the 8-mL VOI. Accurate repositioning
was easily achieved for each monkey by using anatomical landmarks on
coronal, axial, and sagital images (Fig. 1), so that NMR acquisitions were
performed in comparable VOIs. Since PET provided images of the whole brain,
it was necessary to localize the 8-mL VOI on PET images to assess CMRglc from
this volume only. We registered 3D reconstructed PET images with 3D MRI by
using robust and fully automated rigid registration method (48). Registration
allowed one to accurately localize the NMR detected VOI within PET images
and to extract 18F time activity from this VOI.
CMRglcMeasurement by 18F PET. PET sessions. PET experiments were performed
on an ECAT EXACT HR tomograph (Siemens-CTI). After completing a trans-
mission scan with a 68Ga-68Ge source for attenuation correction, 24 emission
scans (63 slices, 4.5-mm isotropic intrinsic resolution) were collected for 60 min
after 18F-FDG i.v. bolus injection (2.5 mCi). To obtain arterial blood function,
blood samples were withdrawn every 15 s during the first 2 min of acquisition;
then, at 2.30, 3, 5, 7, 10, 15, 20, 30, 40, and 50 min. Arterial blood radioactivity
was measured in a cross-calibrated -counter (Cobra Quantum D5003; Perkin-
Elmer). For control of physiological stability, measurements of glycemia, blood
pH, pO2, pCO2, sO2 were performed at the beginning, after 20 min and at the
end of the acquisition protocol.
Flux quantification. The 8-mL VOI was extracted from the 24 PET images as
described above, and the corresponding time activity curve was generated
with regional activity calculated for each frame and plotted vs. time. The time
activity curve was then fitted by using a 2-tissue compartment model in PMod
(PMOD Technologies) (49), under the hypothesis of irreversible phosphoryla-
tion (k4  0). The kinetic constants k1, k2, and k3 describing the exchanges
between the pools of plasmatic 18F-FDG, cytoplasmic 18F-FDG, and cytoplasmic
phosphorylated 18F-FDG-P were derived from this adjustment. The lumped
constant (LC) was fixed to 0.42, according to previous studies (30, 31). Last,
CMRglc was calculated from the values of glycemia, LC, k1, k2, and k3.
VTCA Measurement by Indirect 13C NMR. NMR setup and voxel positioning. MR
experiments were performed on a whole-body 3 Tesla system (Bruker)
equipped with a surface coil placed on top of the head (double-tunable 1H-31P,
Ø  4.5 cm). VTCA sessions started with the acquisition of the 3D MRI and the
positioning the VOI. VOI shimming was performed down to 8 Hz by means
of the FASTMAP algorithm (50), for first- and second-order shim coils.
Indirect 13C NMR spectroscopy. Spectra were collected by using a 1H STEAM
sequence (TE/TM/TR  21/110/2500, 256 transients). Additional localization
was achieved by a B1-InSensitive TRain to Obliterate signal (BISTRO) outer
volume suppression (OVS) pulse train (51), consisting of 15 modules repeated
at increasing RF power levels. Each module was formed by 3 double-band
hyperbolic secant pulses selectively saturating slabs outside the 2	 2	 2 cm3
VOI along the X, Z, and Y directions (52). OVS was combined with VAPOR
water suppression (53). At the beginning of the experiment, a baseline 1H
STEAM spectrum was acquired within the VOI. Then, 1H STEAM spectra were
collected during a 2-step infusion protocol of [U-13C6] glucose. Infusion started
with a 3-min bolus of [U-13C6] glucose (0.3 mL/kg/min, 20% wt/vol), leading
quickly to a 3-fold increase in glycemia: blood glucose concentration before
bolus infusion was typically 3–5 mmolL1 and reached 9–15 mmolL1 after
the bolus. Then, a continuous 2-h i.v. infusion of a 2:1 mixture of [U-13C6] and
unlabeled glucose was performed at lower rate (0.01 mL/kg/min, 20%
wt/vol). This 2-step infusion leads to a stabilization of 13C fractional enrich-
ment (FE) of plasma glucose 55 to 60% after 5 min and until the end of
infusion (52). Control measurements of glycemia were performed by using a
Onetouch glucose meter (Lifescan).
Spectra quantification and VTCA measurement. Measurement of 13C-glutamate
enrichment from the 1H spectra was based on a previously described method
(30, 52). Briefly, the subtraction of 1H spectra acquired during the [U-13C6]
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glucose infusion from the baseline 1H spectrum results in difference spectra
exhibiting only labeled nuclei: mainly glutamate C3 and C4 in the brain; 13C
enrichment has 2 effects on the 1H spectrum: 1H coupled to 13C (satellite
resonance) appear as a doublet, whereas 1H bound to 12C (mother resonance)
decrease. Subtracting a 13C-enriched spectrum from a baseline spectrum
provides a difference spectrum where mother resonances exhibit positive
intensities (at 2.11 ppm for GluC3 and 2.35 ppm for GluC4), whereas 13C
satellite resonances appear antiphased (at 2.85 and 1.85 ppm for GluC4 and at
1.65 and 2.65 ppm for GluC3); 1H difference spectra collected during 13C-
glucose infusion are dominated by changes in mother resonances, as shown
on Fig. 3A; 1H difference spectra were quantified by using Java-based MR user
interface (jMRUI; see ref. 54), which performs time domain analysis of free-
induction decays. An original basis set of simulated 1H difference spectra of
glutamate C4 and C3 13C-enrichment was implemented for the quantitation
based on quantum estimation algorithm (QUEST; see ref. 55) within jMRUI, by
using literature values of resonance frequencies and J-coupling constants (56).
The time courses of C4 and C3 enrichment were first estimated. To assess the
value of the TCA cycle flux VTCA, a single compartment model describing the
incorporation of 13C from blood glucose into brain glutamate was imple-
mented on Matlab (The MathWorks Inc.) (5, 33). The following assumptions
were made: (i) glucose transport through the blood-brain barrier follows a
reversible Michaelis-Menten kinetic, (ii) the exchange rates VX between glu-
tamate and -ketoglutarate and between oxaloacetate and aspartate are
equal, (iii) the rate of the glutamate/glutamine cycling is equal to 0.46	 VTCA
(5). The concentrations of glutamate, glutamine, aspartate, lactate, oxaloac-
etate, and -ketoglutarate, as well as the glucose transport parameters, were
taken from a previous monkey study (52).
VATP Measurement by 31P Saturation Transfer NMR. NMR setup and voxel
positioning. MR experiments were performed on the previously described 3T
system equipped with the same surface coil. VOI positioning and shimming
were performed the same way as for VTCA sessions.
Theory. Consider the chemical equilibrium between inorganic phosphate Pi
and ATP:
Pi-|0
k f
k r
 ATP [2]
where kf and kr are the unidirectional rate constants of ATP synthesis and
hydrolysis, respectively. To derive the rate of ATP synthesis VATP  kf[Pi], kf is
measured by progressively saturating the magnetization of -ATP and ob-
serving the effect on the magnetization of the exchange partner Pi. Then, kf
is derived from the Bloch equations modified for chemical exchange. This
method can be applied to ATP synthesis because the lifetime of Pi (1/kf) is in the
same order as the intrinsic longitudinal relaxation time of Pi T1int. This obser-
vation explains why the saturation transfer method is specifically sensitive to
ATP synthesis, although Pi is involved in several biochemical reactions (12, 13,
17, 18). However, it must be noted that the Pi to ATP conversion catalyzed by
the GAPDH/PGK enzymes at the glycolytic level is fast enough to potentially
contaminate 31P-NMR measured Pi attenuation (20–23).
Saturation Transfer 31P MRS Experiment. The 31P spectra were collected from the
VOI by using an OVS-localized saturation transfer sequence (57). A saturation
pulse (variable length tsat) was followed with a BISTRO OVS pulse train (total
OVS train length tOVS, 310 ms). A 100-s broadpulse was placed immediately
after the OVS module for nonselective excitation. The saturation frequency
was first set to -ATP frequency (7.35 ppm relative to Pi), and spectra were
collected for 4 different values of tsat (0.5, 1.0, 1.5, and 2 s) by using a 2.95-s TR
and 512 transients for each tsat. Then, control spectra without-ATP saturation
were collected. To correct for the RF bleed over effect, control spectra were
acquired with a saturation frequency set to 7.35 ppm relative to Pi (control
saturation symmetric to -ATP) for the same 4 values of tsat. The total acqui-
sition time including shimming for each tsat was 100 min.
Inversion recovery experiment. The T1 of Pi in the presence of chemical exchange
T1mix was measured by using an inversion recovery sequence: a 180° adiabatic
hyperbolic secant pulse (length, 4 ms) set on Pi frequency and a gradient
crusher (length, 2 ms) were placed before the OVS module at variable inver-
sion time TI (TI, time between inversion pulse and acquisition). Note that for
the TI  0 experiment, the inversion pulse was placed between the OVS
module and the acquisition pulse. Repetition time was fixed to 6.4 s to allow
full relaxation of Pi magnetization (T1mix is expected 2 s at 3 Tesla); 31P
spectra were acquired for 7 values of TI (128 transients).
Spectra quantification. All 31P spectra were zero-filled to 2,048 points and
analyzed by using an Advanced Method for Spectral Fitting (AMARES) within
jMRUI (54, 58); 13 31P multiplets were included (24), assuming lorentzian line
shapes. Shimming variations between experiments were corrected relative to
the estimated linewidth of the dominant resonance PCR. Baseline and 2-order
phase corrections were performed. For the saturation transfer experiment,
the averaged Pi attenuation ratio was calculated as the average ratio of Pi
magnetization on -ATP saturation MS over Pi control magnetization MC for
each monkey and each saturation time.
Metabolic modeling and VATP measurement. The time evolution of Pi longitudinal
magnetization can be modeled by using the Bloch equation modified for
chemical exchange between Pi and -ATP:
dMzPi(t)
dt

MzPi
0 MzPi(t)
T1int
k fMzPi(t)  k r MzATP(t) [3]
where MzPi and MzATP are the longitudinal magnetizations of Pi and ATP,
respectively. MzPi0 is the fully relaxed longitudinal magnetization of Pi. Pi
attenuation MS(tsat)/MC(tsat) depends on the user-fixed sequence parameters
(delays tOVS, tsat, and TR, excitation angle ), and on the following unknown
parameters: Pi relaxation time in presence of chemical exchange T1mix (59),
unidirectional rate constant of ATP synthesis kf, and Pi intrinsic relaxation time
in the absence of chemical exchange T1int (57). T1mix was estimated by the
inversion recovery experiment as previously described. TheMS(tsat)/MC(tsat) vs.
tsat curve was fitted by using a nonlinear least squares algorithm leading to the
estimation of the unknown parameters kf and T1int. Monte Carlo simulation
was also performed on this dataset to assess the accuracy on the 2 fitted
parameters. The flux of ATP synthesis VATP was derived from the equation
VATP  kf[Pi], where the cerebral Pi concentration [Pi] was estimated from the
literature (24–29).
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